Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatmentCell Reports MedicineApril 20, 202210.1016/j.xcrm.2022.100608Cited by 22SaveCiteExport RISWatch citationsRelated PapersNo related papers foundPowered by citation graph analysis